Clinical Trial Update: Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant Gemcitabine, Doxorubicin, and Paclitaxel (GAT) in breast cancer patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gemcitabine, Doxorubicin and Paclitaxel (GAT)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED